Harry Meade is SVP & Transgenic Research at GTC BIOTHERAPEUTICS INC (GTCB). They have made 1 open-market trade across 1 company since 2007, most recently 2009-11-02.
CIK 0001241322
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $9K since 2007, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| GTCB | 31,257 | — |
Shares reported on the most recent Form 4, priced at the 2009-11-13 close. 1 holding could not be priced and is excluded from the total.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| GTCB | BUY | 2007-12-14 | 2007-12-14 | $0.90 | $9K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.